- Home
- RCS vs VYGR Comparison
RCS vs VYGR Comparison
Compare RCS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | VYGR |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | US |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 222.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RCS | VYGR |
|---|---|---|
| Price | $5.72 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 191.0K | ★ 571.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $2.65 |
| 52 Week High | $8.00 | $5.55 |
Technical Indicators
Market Signals| Indicator | RCS | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 33.59 |
| Support Level | $5.72 | $3.31 |
| Resistance Level | $6.03 | $3.91 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 12.12 | 6.41 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.